REGENXBIO shares plunge 35% on FDA clinical hold for RGX-121

RGNX Regenxbio Inc

$8.47 +10.14%

View chart & analysis →

1. 1REGENXBIO (RGNX) shares plunge 35% after FDA clinical hold on Hunter syndrome gene therapy RGX-121
2. 2Five CAMPSIITE participants were found to have asymptomatic nodules/cystic masses on spine MRI roughly 3–6 years post-administration; near-term BLA resubmission outlook withdrawn
3. 3Findings are classified as non-serious and likely benign, with no abnormalities on brain MRI; the company will focus on its Duchenne and retinal programs

Source InvestorsHub +2 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →